Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
Scientific title
An Open Label Study of the Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Study type
Description of intervention(s) / exposure
Treatment: Drugs - Ifenprodil

Other: Single Arm Active - Ifenprodil

Treatment: Drugs: Ifenprodil
Ifenprodil 20 mg TID

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
A =50% reduction in the average number of coughs per hour over 24 hours comparing baseline to treatment period using an ambulatory cough monitor
Timepoint [1] 0 0
Baseline and week 12 (=11 weeks of treatment)
Primary outcome [2] 0 0
No worsening of force vital capacity (FVC) in either mL or % predicted
Timepoint [2] 0 0
Baseline and week 12 (=11 weeks of treatment)

Key inclusion criteria
1. Male and female subjects with a diagnosis of IPF established during the previous seven
years according to ATS/ERS/Fleischner criteria.

2. Score = 40 mm on the Cough Severity VAS at Screening

3. Lung function parameters as follows:

1. Forced Vital Capacity (FVC) = 45% of the predicted value at screening.

2. Diffusion lung capacity for carbon monoxide (DLCO) (corrected for Hb) of 30% to
79% of the predicted value at screening.

4. Any existing Standard of Care (SoC) treatment (e.g. pirfenidone or nintedanib) must be
deemed as stable (minimum three months) before enrollment.

5. Subjects must sign and date a written, informed consent form and any required
authorization prior to initiation of any study procedures.
Minimum age
No limit
Maximum age
85 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Currently has significant airways obstruction: Forced Expiratory Volume in 1 s
(FEV1)/Forced Vital Capacity (FVC) ratio of < 0.7 at screening.

2. Has clinical evidence of active infection, including, but not limited to, bronchitis,
pneumonia, sinusitis, urinary tract infection, and cellulitis.

3. Has a history of malignancy within the last 2 years with the exception of basal cell
carcinoma, chronic lymphocytic leukaemia (under observation) and prostate cancer
requiring anti-androgens, localised treatment (minor surgery, radiotherapy) and/or
managed by observation, and squamous cell carcinoma if diagnosed and successfully
treated more than 6 months prior to the study. SCC diagnosed with the past 6 months
will be exclusionary.

4. Patients experiencing cerebral hemorrhage or cerebral infarction at

5. Has any condition other than IPF that, in the opinion of the investigator, is likely
to result in the death of the subject within the next 2 years.

6. Presence of other disease that may interfere with testing procedures or in the
judgement of the Investigator may interfere with trial participation or may put the
patient at risk when participating in this trial.

7. Is likely to receive lung transplantation within the next 12 months.

8. Currently receiving high dose corticosteroid, cytotoxic (e.g., chlorambucil,
azathioprine, cyclophosphamide, methotrexate), vasodilator therapy for pulmonary
hypertension (e.g., bosentan), and or investigational therapy for idiopathic pulmonary
fibrosis (IPF) or administration of such therapeutics within 4 weeks of initial
screening (or 5 half-lives, whichever is longer). A current dose of less than or equal
to 15 mg/day of prednisone or its equivalent is acceptable if the dose is anticipated
to remain stable during the study.

9. Has a history of unstable or deteriorating cardiac or pulmonary disease (other than
IPF) within the previous six months, including, but not limited to, the following:

1. Unstable angina pectoris or myocardial infarction, or percutaneous coronary
intervention within the last 6 months,

2. Congestive heart failure requiring hospitalization,

3. Uncontrolled clinically significant arrhythmias.

10. If female, the subject is pregnant or lactating or intending to become pregnant before
participating in this study during the study and within (5 half- lives plus 30 days)
after last dose of the study drug; or intending to donate ova during such time period.

11. Women considered to be of childbearing potential who do not use highly effective birth
control methods during the study.

12. Known or suspected allergy to the trial drug or the relevant drugs given in the trial.

13. Involvement in a clinical research study within 4 weeks prior to screening and/or
prior enrollment in the study. Participation in registry studies is permitted.

Study design
Purpose of the study
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Vale Medical Practice - Brookvale
Recruitment hospital [2] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [3] 0 0
Westmead Hospital - Westmead
Recruitment hospital [4] 0 0
Cairns Hospital - Cairns
Recruitment postcode(s) [1] 0 0
- Brookvale
Recruitment postcode(s) [2] 0 0
- Concord
Recruitment postcode(s) [3] 0 0
- Westmead
Recruitment postcode(s) [4] 0 0
- Cairns
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Country [2] 0 0
New Zealand
State/province [2] 0 0

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Algernon Pharmaceuticals

Ethics approval
Ethics application status

Brief summary
NP-120 (Ifenprodil) has been shown to mediate anti-inflammatory responses and reduce
pulmonary fibrosis in a murine model of Idiopathic Pulmonary Fibrosis (IPF). In addition,
NP-120 significantly reduced both cough frequency and onset in a guinea pig tussive model.
The purpose of this proof-of-concept trial is to determine the efficacy of NP-120 in the
treatment of IPF and its associated cough.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Nancy Stewart, Ph.D.
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see